Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2001

View Archived Issues

Enhanced version of MetXia to be codeveloped by Oxford BioMedica and PolyMASC

Bioniche bladder cancer trial yields positive interim results

NIH funds will be used to advance development of novel HIV treatments at PTC

Favorable preclinical results reported for Demegen's vaginal microbicide

Genta licenses technology platform for designing novel anticancer treatments

IND filed to investigate Hemolink in chemotherapy-associated anemia

BLA for Zevalin granted priority review by FDA

Pharmacokinetics of Co-102862 investigated in animals using new HPLC method

Update on status of Fabrazyme reported by Genzyme General

Pregabalin may have beneficial effects in the treatment of abdominal pain

Pivotal trial of Ortec's donor site wound treatment shows promising results; PMA filing upcoming

Preclinical studies on interaction of STI-571 with chemotherapeutic agents and radiation

TKT to commence clinical trials of Hunter's syndrome treatment

Remicade is first drug approved for inhibiting progression of joint damage in RA

TRIAD compositions with neuroprotective efficacy reported by Quebec researchers

Centocor acquires worldwide rights to 3DP's orally active direct thrombin inhibitor program

Hydroxamic acid-based MMP inhibitors with selectivity for MMP-2, MMP-9 and/or MMP-13

New agents for HIV and AIDS interact with CCR5 receptor

Kyowa Hakko synthesizes phenylalanine esters intended for atopic dermatitis

Gestilab patents compositions protecting against myocardial oxidative stress

NCI funds development of novel vector that enhances tumor cell radiosensitivity

Cell Genesys reports further promising results from phase I trial of GVAX pancreatic cancer vaccine

FDA agrees to review BLA for first intranasal flu vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...